Micardis® in Patients With Essential Hypertension | NCT02187705 | Trialant

Micardis® in Patients With Essential Hypertension | NCT02187705 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Patients with normotension at baseline			Drug: Telmisartan tablets
Patients with essential hypertension at baseline			Drug: Telmisartan tablets
Patients with isolated hypertension at baseline			Drug: Telmisartan tablets

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Telmisartan tablets	Drug	All patients were treated with different doses of telmisartan for 14 days	Patients with essential hypertension at baseline Patients with isolated hypertension at baseline

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Changes from baseline in blood pressure	Evaluation was performed separately for three patient groups depending on their hypertension status at baseline (normotension, essential hypertension and isolated hypertension)	Up to 14 days
Number of patients with adverse events		Up to 14 days

Intervention Browse Module